Introduction
Most studies of health effects in humans exposed to complex air-pollutant mixtures have used such outcome measures as hospital admission rates during air pollution episodes, symptom reports from questionnaires or diaries, and disease prevalence or mortality rates in communities with different levels of air pollutants. A few studies in controlled exposure settings have attempted to assess the combined as well as separate effects of mixture components. Such approaches provide useful information; but studies of overt disease often are insensitive to low-dose exposure effects, and they focus on the extreme end of the disease spectrum, where only a small proportion of the exposure-related disease burden occurs.
Biological markers of intermediate health outcomes (i.e., early pathologic changes or events predictive of disease) could provide a superior alternative to traditional measures of pollutant-related disease. Markers can have greater sensitivity to exposure effects, they may appear sooner after exposure and at younger ages, and they may detect a greater proportion of the exposure-related disease burden compared to past. Because some early pathologic changes detected by markers do not progress to symptomatic conditions, more people will show positive marker responses than overt disease; so studies using markers can potentially have increased statistical power due to the more numerous outcomes. However, the markers are useful only to the extent that they have a known relationship to clinical diseases of interest.
In general, biological markers are indicators of events occurring in the body that are difficult to measure directly. Markers can indicate that an exposure, a response to exposure, or an early pathologic change has occurred; other markers, often enzyme phenotypes, indicate an individual's increased susceptibility to disease from a particular exposure. Such markers differ from genetic markers, which are usually defined in the current genetic literature as discrete phenotypes controlled by genes The rationale for using nontarget tissues and cells for assessing evidence of early disease is that pathologic changes observed in nontarget tissues often occur in the target tissues. For example, exposure to acid aerosols and oxidants can exacerbate airway hyperreactivity in asthmatics (1) , with a resulting increase in pulmonary and blood eosinophils. Chronic E1 and E2, cause the same marker response through independent pathways, they increase the overall marker response rate in an additive manner; but relative measures of association (e.g., relative risk, odds ratio, etc.) are based on the assumption of a multiplicative model of association. As a result, the relative risk of the response due to El will be influenced by the background incidence of the response due to E2. In this situation, use of the risk difference rather than relative risk to compare marker responses in persons exposed and unexposed to E1 helps avoid the problem of dilution from a high background incidence from E2.
Another strategy for mitigating the problem of dilution is to stratify an overall group of end points into its more homogeneous components (7 
Sensiiity
In many instances, different markers can be used to detect the same outcome. Inflammation, for example, involves numerous physiological changes that can be used as markers of the inflammatory response. For a given degree of inflammation, however, some markers will be easier to detect than will others. Markers that detect the mildest inflammation (i.e., those that are positive with the lowest exposures) would have the greatest sensitivity.
An animal study (8) The timing of measurements is less important for markers of chronic exposure-related changes. Irreversible airspace enlargement, for example, can be measured long after exposure ends, and it will reflect cumulative exposure effects. Altered populations of alveolar epithelial cells due to oxidant air pollution exposure eventually revert to normal proportions, but these markers can probably be detected for at least several weeks after the end of exposure. Timing is still important in the sense that the exposure must be sufficiently long for the marker response to occur. Note that for some markers of chronic pathogenic processes, such as the markers ofconnective tissue degradation in the study by Evans et 
